Taken together, our findings suggest that studying IL-22 production by allergen-specific CLA+ memory T cells can be a useful approach to identify a subgroup of AD patients with an activated IL-22 pathway in lesional skin, who could benefit from IL-22–targeted therapies. This evidence concerns the gene IL22 and Alzheimer disease.